| |
RA, DMARD (n = 10)
|
RA, anti-TNF (n = 13)
|
p value
|
|---|
|
ESR, mm/H
|
9 [7–21]
|
6 [6–17]
|
0.689
|
|
Disease activity score (DAS28)
|
2.24 [1.3–2.5]
|
1.98 [1.8–2.2]
|
1.000
|
|
Anti-CCP positive (%)
|
7 (70)
|
8 (61)
|
0.673
|
|
Rheumatoid factor positive (%)
|
8 (80)
|
7 (54)
|
0.192
|
|
Disease duration, years
|
7.8 [4.0–10.2]
|
13.3 [9.3–20.2]
|
0.012
|
|
Anti-TNF
|
n/a
| |
n/a
|
|
- Adalimumab
| |
10
| |
|
- Certolizumab
| |
1
| |
|
- Etanercept
| |
1
| |
|
Disease duration until start anti-TNF, years
|
1.2 [1.0–1.7]
|
5.6 [4.3–9.1]
|
0.001
|
|
Anti-TNF withdrawal attempts, yes/no
|
10/0
|
9/4
|
n/a
|
|
DMARD
| | |
n/a
|
|
- Methotrexate
|
9
|
11
| |
|
- Sulfasalazine
|
1
| | |
|
Other Rx
| | | |
|
- Statin
|
1
|
1
|
0.848
|
|
- Antihypertensive
|
5
|
5
|
0.580
|
- Values are n (%), mean ± SD or median [IQR,] for skewed data
-
RA rheumatoid activity, DMARD disease-modifying antirheumatic drug, TNF tumor necrosis factor, ESR erythrocyte sedimentation rate, DAS28 disease activity score based on 28 joints, CCP cyclic citrullinated peptide
